-
1.发明授权
公开(公告)号：EP1976883B1
公开(公告)日：2012-10-03
申请号：EP07718000.8
申请日：2007-01-17
申请人： Medarex, Inc. , Synthon B.V.
发明人： BLACK, Amelia, Nancy , PASSMORE, David, B. , SRINIVASAN, Mohan , DICKEY, Lynn, F. , COX, Kevin, M. , PEELE, Charles, G. , WANG, Ming-Bo
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/13 , C07K2317/21 , C07K2317/41 , C07K2317/72 , C07K2317/732
-
2.发明公开CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF 审中-公开化学品连接器在IHRE KONJUGATE上进行了基础研究
公开(公告)号：EP2114454A2
公开(公告)日：2009-11-11
申请号：EP07870071.3
申请日：2007-12-28
申请人： MEDAREX, INC.
发明人： SUFI, Bilal , GUERLAVAIS, Vincent , CHEN, Liang , GANGWAR, Sanjeev , ZHANG, Qian , PASSMORE, David, B.
IPC分类号： A61K47/00
CPC分类号： C07K5/06052 , A61K47/552 , A61K47/556 , A61K47/65 , A61K47/6809 , A61K47/6851 , A61K49/0002 , C07D403/14 , C07D487/04 , C07K5/06078 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/1008
摘要： The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
摘要翻译： 本公开提供了药物 - 配体缀合物和药物可切割底物缀合物，其是有效的细胞毒素。 本公开还涉及含有药物 - 配体缀合物的组合物以及使用它们的治疗方法。
-
3.发明公开
公开(公告)号：EP1976883A2
公开(公告)日：2008-10-08
申请号：EP07718000.8
申请日：2007-01-17
申请人： MEDAREX, INC.
发明人： BLACK, Amelia, Nancy , PASSMORE, David, B. , SRINIVASAN, Mohan , DICKEY, Lynn, F. , COX, Kevin, M. , PEELE, Charles, G. , WANG, Ming-Bo
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/13 , C07K2317/21 , C07K2317/41 , C07K2317/72 , C07K2317/732
摘要： The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to Iyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
-
公开(公告)号：EP1907424A2
公开(公告)日：2008-04-09
申请号：EP06786260.7
申请日：2006-06-30
申请人： MEDAREX, INC.
发明人： KORMAN, Alan, J. , SELBY, Mark, J. , WANG, Changyu , SRINIVASAN, Mohan , PASSMORE, David, B. , HUANG, Haichun , CHEN, Haibin
IPC分类号： C07K16/28
CPC分类号： C07K16/2827 , A61K45/06 , A61K47/6817 , A61K47/6825 , A61K47/6849 , A61K2039/505 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K2317/21 , C07K2317/41 , C07K2317/56 , C07K2317/567 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/77 , C07K2317/92 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466
摘要： The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-Ll with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-Ll, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-Ll antibodies.
-
公开(公告)号：EP1899379A2
公开(公告)日：2008-03-19
申请号：EP06785284.8
申请日：2006-06-20
申请人： MEDAREX, INC.
发明人： RAO-NAIK, Chetana , KING, David, John , LIU, Jie , HUANG, Haichun , PASSMORE, David, B. , BELL, Alasdair, Fraser , CARDARELLI, Josephine, M. , PAN, Chin , THI DO, To, Uyen , CHEN, Sharline
CPC分类号： C07K16/2803 , A61K47/6817 , A61K47/6825 , A61K47/6849 , A61K2039/505 , C07K2317/21 , C07K2317/41 , C07K2317/732 , C07K2317/77 , Y02A50/412
摘要： The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.
摘要翻译： 本公开提供分离的单克隆抗体，特别是以高亲和力特异性结合CD19的人单克隆抗体。 还提供了编码这种CD19抗体的核酸分子，表达载体，宿主细胞和用于表达CD19抗体的方法。 还提供了免疫偶联物，双特异性分子和包含CD19抗体的药物组合物。 公开了用于检测CD19的方法，以及用于治疗各种B细胞恶性肿瘤（包括非霍奇金淋巴瘤）的方法。
-
6.发明公开MONOCLONAL ANTIBODIES AGAINST PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LACKING IN FUCOSYL RESIDUES 审中-公开单克隆抗体的前列腺特异膜抗原，在岩藻糖REMAINS MISSING
公开(公告)号：EP1851251A2
公开(公告)日：2007-11-07
申请号：EP06735490.2
申请日：2006-02-17
申请人： MEDAREX, INC.
CPC分类号： C07K16/3069 , A61K2039/505 , C07K2317/23 , C07K2317/41 , C07K2317/732 , C07K2317/77
摘要： The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.019 秒)
